KOLADE AJAYI: Open Payments
NPI 1427521186 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$500 in 29 payments from 8 companies in 2025. Trend: 2023 $120 · 2024 $258 · 2025 $500
Food & beverage: $500
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $234 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
| ABBVIE INC. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Neurocrine BioSciences, Inc. | 1 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Lundbeck LLC | 1 | $18 |
Products named: REXULTI, COBENFY, CAPLYTA, VRAYLAR, INGREZZA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
